MicroPort Scientific Corporation

Chinese developer of interventional medical products with life-saving solutions and treatments

A Chinese medical technology company focused on interventional medical devices

MicroPort is a medical device company focused on developing, manufacturing, and marketing high-end medical devices globally. The company has a diverse product portfolio, with its products being used once every 30 seconds on average across more than 2,000 major hospitals in China and in 24 other countries in APAC, South America, and Europe. A majority of MicroPort’s revenue is derived from drug eluting stents, but growth in other cardiovascular, endovascular, and neurovascular devices combined with new market entries into electrophysiological devices and surgical management have significantly accelerated its global diversification. Through its significant R&D spending, MicroPort is dedicated to becoming a global enterprise capable of providing the most affordable medical products and technologies to serve patients world-wide. MicroPort is headquartered in Shanghai, China, and successfully completed its IPO in HongKong in late 2010.

  • Shanghai, People's Republic of China
  • SEHK: 853

  • Contact:
    Immanuel Thangaraj
  • Formerly Known As: MicroPort Medical
  • IPO
  • Exit date: September 24, 2010

Related News

“Essex Woodlands was the only US investor in MicroPort prior to MicroPort going public. Essex Woodlands has a deep understanding of our products and growth potential and provided valuable support in the development of the company, especially as it transitioned into a public company. ”

Michael Zhang

Former President, MicroPort Chairman, Otsuka China Investments

Testimonials and endorsements reflect portfolio company management’s opinions and beliefs regarding the company and the investment. Such opinions and beliefs are subjective, do not represent a complete assessment of the company, the market or EW’s overall investment performance and cannot be independently verified. Such statements are being offered as references for purposes of demonstrating the benefits of working with the EW team and not for the purpose of soliciting investors. Portfolio company executives receive/received a salary and economics from the portfolio company. No executives were paid for their testimonial or endorsement. There is a conflict of interest in these unpaid testimonials and endorsements in that all speakers stand to benefit from EW’s success and they work/worked for an EW portfolio company.